Angus Liu is a Deputy Editor at Fierce Pharma. He specializes in areas related to medicine and healthcare, with a focus on pharmaceuticals, healthcare technology, and business economics, covering topics such as oncology, pharmaceutical regulation, and immunotherapy. Angus is featured in Fierce Biotech, NewsBreak, and Fierce Pharma.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Angus Liu's coverage predominantly focuses on the healthcare and pharmaceutical industry. His articles reflect a strong emphasis on drug development, FDA approvals, clinical trials, and specific medications within the pharmaceutical industry.
Given this focus, Angus would likely be receptive to pitches from experts who have in-depth knowledge of drug development processes or regulatory affairs in the pharmaceutical industry. Pitches offering insights into recent clinical trial outcomes or FDA announcements related to new drugs may also capture his interest.
Sources with access to relevant data or those involved in government announcements pertaining to healthcare regulation could also provide valuable perspectives for Angus's coverage. It is important for potential sources to offer fact-based analysis and credible commentary that aligns with the themes covered in Angus's articles.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angus Liu
Fresh off the excitement of Rasonque’s big splash in pancreatic cancer, the oncology community has another impressive clinical win to celebrate.
By: Angus Liu
Sacituzumab tirumotecan, or sac-TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a
By: Angus Liu
With ivonescimab's first phase 3 win outside lung cancer and a $2 billion investment from AstraZeneca in its U.S. partner Summit Therapeutics, Akeso
By: Angus Liu
AstraZeneca has offered a detailed look at the phase 3 non-small cell lung cancer data that finally position its Hutchmed-partnered Orpathys for an FDA approval more than five years after the MET inhibitor's initial go-ahead in China.
By: Angus Liu
Buoyed by a clean sweep of five positive phase 3 readouts in China, Bristol Myers Squibb’s Chief Medical Officer, Cristian Massacesi, M.D., is voicing growing confidence in the company's first-in-c
By: Angus Liu
As a cornerstone of Merck & Co.'s post-Keytruda oncology strategy, sac-TMT has cleared a clinical milestone.
By: Angus Liu
Two late-stage clinical failures of high-value projects have not changed CEO Vas Narasimhan's projection for Novartis over the next 10 years.
By: Angus Liu
Shortly after Jazz Pharmaceuticals licensed the HER2-targeted bispecific antibody zanidatamab from Zymeworks in 2022, Rob Iannone, M.D., received
By: Angus Liu
Eli Lilly is consolidating its U.S. and international commercial divisions into a unified department, tapping current U.S. head Ilya Yuffa in a newly created role as president of Lilly Global Markets.
By: Angus Liu
Even as a wave of clinical trial wins bolsters its momentum, Merck & Co. is prioritizing ongoing pipeline and commercial expansions over near-term margin growth, hoping to gird its long-term prospects past Keytruda's loss of exclusivity.
